FGEN FibroGen Inc.

FibroGen to Present at Upcoming Investor Conferences

FibroGen to Present at Upcoming Investor Conferences

SAN FRANCISCO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences:

  • 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 at 3:40 PM Eastern Time
  • Cowen 41st Annual Health Care Conference on March 2, 2021 at 12:50 PM Eastern Time

A live audio webcast will be available on the “Events & Presentations” section of the FibroGen Investor webpage at A replay will be available for approximately 30 days.

About FibroGen

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). For more information, please visit

Contact:

FibroGen, Inc.

Investors:

Michael Tung, M.D.

Corporate Strategy / Investor Relations

1.415.978.1434

Media:

Jennifer Harrington

+1.610.574.9196



EN
12/02/2021

Underlying

FGENFibroGen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FibroGen Inc.

 PRESS RELEASE
Free
FGEN FIBROGEN INC.

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Pha...

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who prog...

February 23, 2026 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

Kyntra Bio to Participate in Upcoming Investor Conferences

Kyntra Bio to Participate in Upcoming Investor Conferences SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation Date & Time: Thursday, February 26, 2026, 2:40-3:10 PM ET Location: Virtual Webcast: Leerink Global Healthcare ConferenceFormat: Corporate Presentation Date & Time: Wednesday, March 11, 2026, 2:20-2:50 PM ETLocation: Miami, FL Webc...

February 17, 2026 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Mome...

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum  Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq under the trading symbol “KYNB” effective January 8th SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), today announced it is rebranding the company to Kyntra Bio, representing the next step of the transformation of the Company and its focus on oncology and rare disease assets. The Compan...

January 7, 2026 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

Roxadustat Granted Orphan Drug Designation for the Treatment of Myelod...

Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted roxadustat Orphan Drug Designation for the treatment of myelodysplastic syndromes (MDS). “The Orphan Drug Designation granted to roxadustat for MDS underscores the significant treatm...

December 15, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit

FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11 at 12:15 PM ET at the Sofitel New York. FibroGen’s management team wi...

December 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch